Gossamer Bio, Inc.

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an inhaled small-molecule inhibitor designed to treat pulmonary hypertension (PH), including pulmonary arterial hypertension and PH associated with interstitial lung disease. The company targets large patient populations with significant unmet medical needs in the US and Europe, where PAH affects an estimated 50,000 to 70,000 patients and PH-ILD prevalence is similarly substantial, and where current therapies provide symptom management but no cures. Gossamer generates revenue through milestone payments and royalties under licensing and collaboration agreements with pharmaceutical partners, including a joint development and commercialization partnership with Italian pharma company Chiesi that provides upfront funding and cost-sharing for clinical development and commercial rollout.